- Home
- RNR vs ELAN Comparison
RNR vs ELAN Comparison
Compare RNR & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNR | ELAN |
|---|---|---|
| Founded | 1993 | 1954 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 11.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | RNR | ELAN |
|---|---|---|
| Price | $294.12 | $22.84 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 9 |
| Target Price | ★ $307.14 | $27.63 |
| AVG Volume (30 Days) | 348.7K | ★ 3.9M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,715,000,000.00 |
| Revenue This Year | N/A | $7.97 |
| Revenue Next Year | $3.25 | $5.21 |
| P/E Ratio | $5.42 | ★ N/A |
| Revenue Growth | N/A | ★ 6.22 |
| 52 Week Low | $219.00 | $8.02 |
| 52 Week High | $315.88 | $27.72 |
Technical Indicators
Market Signals| Indicator | RNR | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 37.91 |
| Support Level | $235.78 | $20.41 |
| Resistance Level | $312.68 | $23.70 |
| Average True Range (ATR) | 6.77 | 0.97 |
| MACD | -1.95 | -0.34 |
| Stochastic Oscillator | 30.45 | 8.68 |
Price Performance
Historical ComparisonAbout RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.